Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex
    1.
    发明授权
    Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex 失效
    用于包含锝-99m氮化物异复合物的诊断成像的放射性药物

    公开(公告)号:US07445765B2

    公开(公告)日:2008-11-04

    申请号:US10332707

    申请日:2001-07-25

    IPC分类号: A61K49/00

    CPC分类号: A61K51/02 A61K51/0476

    摘要: A radiopharmaceutical for diagnostic imaging containing as an active ingredient a technetium-99m nitride heterocomplex comprising technetium-99m nitride and two different ligands coordinated therewith, i.e., a bisphosphinoamine compound as a π electron acceptor and a bidentate ligand as a π electron donor and represented by the following formula (I): [99mTc(N)(PNP)(XY)]+ (I)wherein 99mTc(N) is technetium-99m nitride, PNP is a bisphosphinoamine compound and XY is a bidentate ligand, is markedly accumulated in heart and adrenal glands and hence is useful for radiodiagnostic imaging of heart and adrenal glands.

    摘要翻译: 用于诊断成像的放射性药物,其包含锝-99m氮化物异复合物作为活性成分,其包含锝-99m氮化物和与其配位的两种不同配体,即作为pi电子受体的双膦胺化合物和作为pi电子供体的二齿配体, 以下式(I):其中99m Tc(N(N))其中99m Tc(N)(PNP)(XY) )是锝-99m氮化物,PNP是双膦胺化合物,XY是双齿配体,明显地积聚在心脏和肾上腺中,因此可用于心脏和肾上腺的放射诊断成像。

    Method for the reduction of oxygenated compounds of rhenium or technetium
    3.
    发明授权
    Method for the reduction of oxygenated compounds of rhenium or technetium 失效
    还原铼或锝氧化化合物的方法

    公开(公告)号:US6127530A

    公开(公告)日:2000-10-03

    申请号:US269898

    申请日:1999-06-04

    CPC分类号: A61K51/0478

    摘要: The present invention relates in general to a method for the reduction of oxygenated compounds of rhenium and technetium and in particular to the reduction of perrhenate or pertechnetate ions.More particularly, the invention relates to reactions for the reduction of the said oxygenated compounds which are carried out in the course of the preparation of complexes of the radionuclides .sup.186 Re, .sup.188 Re and .sup.99m Tc; in these reactions, the radionuclide perrhenate or pertechnetate ion is reduced in the presence of a reducing agent and a ligand which can form a complex with the radionuclide in its reduced oxidation state.

    摘要翻译: PCT No.PCT / EP97 / 05448 Sec。 371日期1999年6月4日第 102(e)日期1999年6月4日PCT 1997年10月3日PCT PCT。 第WO98 / 14219号公报 日本公开日1998年4月9日本发明一般涉及还原铼和锝的含氧化合物的方法,特别涉及铼酸盐或高锝酸盐离子的还原。 更具体地,本发明涉及在制备放射性核素186Re,188Re和99mTc的络合物的过程中还原所述含氧化合物的反应; 在这些反应中,在还原剂和可以与其还原氧化态的放射性核素形成络合物的还原剂和配体的存在下,将高铼酸根离子或高锝酸根离子还原。

    Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex
    5.
    发明申请
    Radiopharmaceutical for diagnostic imaging containing a technetium-99m nitride heterocomplex 审中-公开
    用于包含锝-99m氮化物异复合物的诊断成像的放射性药物

    公开(公告)号:US20080267868A1

    公开(公告)日:2008-10-30

    申请号:US11889127

    申请日:2007-08-09

    IPC分类号: A61K51/00

    CPC分类号: A61K51/02 A61K51/0476

    摘要: A process for diagnostic imaging of heart or adrenal glands of a human being comprises administering to the human being a radiopharmaceutical containing as an active ingredient a technetium-99m nitride heterocomplex comprising technetium-99m nitride and two different ligands coordinated therewith, i.e., a bisphosphinoamine compound and a bidentate ligand and represented by the formula (1): [99mTc(N)(PNP)(XY)]+. In this formula, 99mTc(N) is technetium-99m nitride, PNP is a bisphosphinoamine compound and XY is a bidentate ligand as described in the specification. The compound of the formula is markedly accumulated in heart and adrenal glands and hence is used for radiodiagnostic imaging of heart and adrenal glands.

    摘要翻译: 用于人的心脏或肾上腺的诊断成像的方法包括向人体施用含有作为活性成分的锝-99m氮化物异复合物的放射性药物,其包含锝-99m的氮化物和与其配位的两种不同的配体,即双膦胺化合物 和二齿配体,由式(1)表示:[99m Tc(N)(PNP)(XY)] + SUP。 在该式中,99m Tc(N)是锝-99m的氮化物,PNP是双膦胺化合物,并且XY是如说明书中所述的二齿配体。 该配方的化合物显着积累在心脏和肾上腺,因此用于心脏和肾上腺的放射诊断成像。

    Radioactive transition metal nitride heterocomplex
    6.
    发明授权
    Radioactive transition metal nitride heterocomplex 有权
    放射性过渡金属氮化物杂复合物

    公开(公告)号:US06270745B1

    公开(公告)日:2001-08-07

    申请号:US09331237

    申请日:1999-06-17

    IPC分类号: A61K5100

    摘要: The present invention provides a single radioactive transition metal nitride heterocomplex which permits labeling of a physiologically active substance such as a peptide, hormone or the like without impairing the activity of the substance. The radioactive transition metal nitride heterocomplex of the present invention is represented by the following formula (I): (M≡N)XY  (I) wherein a radioactive transition metal M is radioactive technetium or radioactive rhenium, N is a nitrogen atom, X is a diphosphine compound or a diarsine compound, and Y is a bindentate ligand having a combination of electron-donating atoms.

    摘要翻译: 本发明提供了一种单一的放射性过渡金属氮化物异复合体,其允许在不损害物质活性的情况下标记生理活性物质如肽,激素等。 本发明的放射性过渡金属氮化物异构复合体由下式(I)表示:其中放射性过渡金属M为放射性锝或放射性铼,N为氮原子,X为二膦化合物或胂系化合物, Y是具有给电子原子的组合的结合配体。